Literature DB >> 21200385

A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.

Walayat Shah1, Xiaofei Yan, Li Jing, Yi Zhou, Hongwei Chen, Yili Wang.   

Abstract

In this study, 40 biopsy samples collected from cervical cancer patients at the First Affiliated Hospital of Xi'an Jiaotong University, China, were retrospectively assessed using immunohistochemistry for CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TILs) and were analyzed for the expression of FOXP3, OX40, granzyme B (GrB) and perforin (Prf). The proliferating index of the TILs was determined by assessing Ki67 expression. We determined the prognostic value of low and high numbers of TILs on survival by performing Kaplan-Meier analysis using median values as the cut-off points. Except for the number of CD4(+)FOXP3(+) regulatory T cells (Tregs) and the CD4/CD8 ratio, none of the CD4(+), CD8(+), OX40(+), GrB(+) or Prf(+) TILs were associated with the overall 5-year survival rate. The 5-year survival rate was significantly lower in patients who had a high percentage of Tregs as compared with the those who had a lower percentage (35.3% versus 88.9%, P=0.001), while the 5-year survival rate was significantly higher in patients with a high CD4/CD8 ratio as compared with patients who had a low CD4/CD8 ratio (82.4% versus 44.4%, P=0.029). When we considered the deaths and surviving cases as separate groups, we found that both the number of CD4(+) T cells and the CD4/CD8 ratio were significantly lower in patients who died as compared with those who survived (26.33±11.80 versus 47.79±38.18, P=0.023 and 0.60±0.25 versus 1.17±1.02, P=0.019, respectively). In conclusion, decreased proportions of tumor-infiltrating CD4(+) T cells with high percentages of Tregs and reversed CD4/CD8 ratios were significantly associated with the clinical outcome of patients with cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21200385      PMCID: PMC4002991          DOI: 10.1038/cmi.2010.56

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  57 in total

1.  Cancer. T cells a boon for colon cancer prognosis.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

2.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

3.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

Authors:  Junliang Fu; Dongping Xu; Zhenwen Liu; Ming Shi; Ping Zhao; Baoyun Fu; Zheng Zhang; Huiyin Yang; Hui Zhang; Chunbao Zhou; Jinxia Yao; Lei Jin; Huifen Wang; Yongping Yang; Yang-Xing Fu; Fu-Sheng Wang
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

4.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.

Authors:  Sytse J Piersma; Ekaterina S Jordanova; Mariëtte I E van Poelgeest; Kitty M C Kwappenberg; Jeanette M van der Hulst; Jan W Drijfhout; Cornelis J M Melief; Gemma G Kenter; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

5.  Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix.

Authors:  Sylvain Monnier-Benoit; Frédéric Mauny; Didier Riethmuller; Jean-Sébastien Guerrini; Mihai Căpîlna; Sophie Félix; Estelle Seillès; Christiane Mougin; Jean-Luc Prétet
Journal:  Gynecol Oncol       Date:  2006-01-20       Impact factor: 5.482

6.  Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma.

Authors:  Gerhard G Grabenbauer; Godehard Lahmer; Luitpold Distel; Gerald Niedobitek
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

7.  Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation.

Authors:  Esther Unitt; Aileen Marshall; William Gelson; Simon M Rushbrook; Susan Davies; Sarah L Vowler; Lesley S Morris; Nicholas Coleman; Graeme J M Alexander
Journal:  J Hepatol       Date:  2006-02-28       Impact factor: 25.083

8.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

Authors:  Sjoerd H van der Burg; Sytse J Piersma; Annemieke de Jong; Jeanette M van der Hulst; Kitty M C Kwappenberg; Muriel van den Hende; Marij J P Welters; Jon J Van Rood; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Rienk Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-05       Impact factor: 11.205

Review 9.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.

Authors:  Gavin P Dunn; Ian F Dunn; William T Curry
Journal:  Cancer Immun       Date:  2007-08-13

10.  Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer.

Authors:  B S Nedergaard; M Ladekarl; H F Thomsen; J R Nyengaard; K Nielsen
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

View more
  87 in total

1.  Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance.

Authors:  Bin-Quan Wang; Chun-Ming Zhang; Wei Gao; Xu-Feng Wang; Hai-Li Zhang; Ping-Chang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

Review 2.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 3.  Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.

Authors:  Paul Mayor; Kristen Starbuck; Emese Zsiros
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

4.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Authors:  Laurene S Cheung; Juan Fu; Pankaj Kumar; Amit Kumar; Michael E Urbanowski; Elizabeth A Ihms; Sadiya Parveen; C Korin Bullen; Garrett J Patrick; Robert Harrison; John R Murphy; Drew M Pardoll; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

6.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

7.  Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer.

Authors:  Liang Wang; Donger Zhou; Haitao Ren; Yan Chen
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

8.  Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.

Authors:  Ledi Kuang; Yuedong He
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

Review 9.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

10.  Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model.

Authors:  Ai-Xia Dou; Li-Li Feng; Xiao-Qian Liu; Xin Wang
Journal:  Cell Mol Immunol       Date:  2012-09-24       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.